A Danish drugmaker is looking to list its shares on the Nasdaq.

Copenhagen-based Genmab said Tuesday that it had filed a Form F-1 with the Securities and Exchange Commission for a potential offering of shares on the US market, wherein it would trade under the ticker symbol GMAB. The company already trades on the Copenhagen Stock Exchange, officially called the Nasdaq Copenhagen, under the ticker symbol GEN. Its market capitalization 75 billion Danish kroner, or $11.2 billion. It also trades on the over-the-counter market in the US under the ticker symbol GMXAY.

The company is looking to raise $500 million in its US market debut, according to the Form F-1. Morgan Stanley is the lead book runner, joined by BofA Merrill Lynch, Guggenheim Securities, Jefferies and RBC Capital Markets.

The company’s lead product is Darzalex (daratumumab), a CD38-targeting monoclonal antibody partnered with Johnson & Johnson subsidiary Janssen and approved by the Food and Drug Administration for the blood cancer multiple myeloma. Another approved product it has is Arzerra (ofatumumab), a monoclonal antibody that targets the CD20 antigen and is approved for treating chronic lymphocytic leukemia, partnered with Swiss drugmaker Novartis.

Darzalex is currently the only FDA-approved monoclonal antibody targeting CD38, though a potential competitor, French drugmaker Sanofi’s isatuximab, is in Phase III development, with data slated for presentation at the upcoming American Society of Clinical Oncology meeting this weekend. Other CD20-targeting drugs include two by Roche, namely Rituxan (rituximab) and Gazyva (obinutuzumab). A biosimilar version of Rituxan, Celltrion’s Truxima (rituximab-abbs), is also approved.

Drugs in Genmab’s pipeline include two antibody-drug conjugates for solid tumors respectively in Phase II and Phase I/II development, tisotumab vedotin and enapotamab vedotin, both partnered with Seattle Genetics. The company also has a drug in Phase III development for thyroid eye disease, teprotumumab, partnered with Horizon Pharma. Other drug candidates in early development are partnered with Janssen, Bristol-Myers Squibb and others companies, along with about 20 preclinical programs. In its Form F-1, the company said it hopes to launch its own drug product by 2025.

Related

Desperate Pharmaceutical Company Hits Rock Bottom, Names Martin Shkreli CEO

Everyone's favorite price-gouging emo-rapping hedge fund-dropout is now CEO of a publicly-traded company.

FBI Arrests Martin Shkreli On Fraud Charges, Because Karma Isn't A Statute

The hedge fund manager turned pharma CEO should have "turned" more carefully.

Happy Holidays, Martin Shkreli Is Still The Worst

Happy Thanksgiving from Martin Shkreli.

Congratulations, You've Really Hurt Valeant's Feelings

The much-reviled pharma company is feeling sad, and oh-so-lonely.

dumipofamilytree

Blue Apron IPO Is A Clusterfuck Recipe-in-a-Box.

The cash-hemorrhaging DIY dinner startup is hoping that people will hold its stock longer than they use its product.

Screen Shot 2019-10-07 at 4.58.40 PM

Don't EVEN Talk To Chuck Schwab About These Money-Losing Tech Stocks

Charles Schwab thinks this modern IPO market might be bullsh!t.